Skip to main content

Exercise More Important Than Diet in Children's Body Fat


June 1, 2012 (San Francisco, California) — How much of a child's body is fat and how much is lean depends more on physical activity than on diet, researchers reported here at the American College of Sports Medicine 59th Annual Meeting.
A study of 734 middleclass Australian children of average weight showed that those with a higher ratio of fat to lean were more active, but actually consumed fewer calories. "The kids who are fatter eat less and they exercise a hell of a lot more," said Richard D. Telford, PhD, an exercise physiologist at the Australian National University in Canberra.
Whether diet or exercise matters more in body composition has stimulated vigorous debate, with leading experts taking opposite positions, Dr. Telford said.
To help answer the question, Dr. Telford and his colleagues examined suburban children whose socioeconomic status was similar to the Australian average. They took measurements when the children were 8, 10, and 12 years of age.
They used a variety of instruments to measure the health of the children. Dual-energy x-ray absorptiometry was used to obtain body fat percentage; 7-day pedometers were used to obtain average daily physical activity; 7-day accelerometers were used to obtain average daily moderate to vigorous physical activity (in the final year only); and parent- or teacher-assisted 2-day records were used to measure total daily energy, fat, carbohydrate, and sugar intake.
They also recorded the stage of puberty, using Tanner staging.
Dr. Telford showed a graph of percent body fat and Physical Activity Index scores (approximately equal to the square root of the number of steps per day); increased body fat correlated with increased physical activity in a straight line. The correlation was statistically significant for boys and girls (P < .001 for both).
On another graph, more moderate to vigorous physical activity corresponded to a lower percentage of body fat. Once again, the finding was significant (P < .001 for boys and P < .01 for girls).
"If we looked at any of the age groups separately, we got exactly the same results," said Dr. Telford.
To give an example, Dr. Telford said that an average 12-year-old boy in the study would have half a percentage point less body fat if he took 2100 steps per day more than another boy of the same age (e.g., 24.5% vs 25.0% body fat).
Dr. Telford and colleagues also found a correlation between diet and body fat for boys, but it was the opposite of what they expected. The fatter boys consumed less sugar, less fat, fewer carbohydrate calories, and fewer total calories than the leaner ones.
These correlations in boys were only statistically significant for carbohydrates (P = 0.1), but they approached significance for sugar (P < .06) and total calories (P = .05).
The researchers found no significant relation between diet and body composition in girls.
"I don't want to underestimate the importance of diet," said Dr. Telford. "That would be foolish."
But in this population, physical activity clearly makes a bigger difference to body composition than diet, he concluded.
Session moderator John M. Jakicic, PhD, an exercise physiologist from the University of Pittsburgh in Pennsylvania, asked whether the percentage of fat was the most important measurement to target when trying to improve children's health.
"I think it might be the total amount of fat that's critical," he said. He isn't ready to give up using body mass index either. "The more body weight you carry, the more physical problems you have."
Other research has shown the importance of diet on these measures of health, he said.
Finally, he pointed out that public health advocates are already focused on activity in children.
"Physical activity is an important target," he said. "How to get the lowest-activity kids to be more active is the greatest challenge."
Dr. Telford and Dr. Jakicic have disclosed no relevant financial relationships.
American College of Sports Medicine (ACSM) 59th Annual Meeting: Abstract 656. Presented May 31, 2012.

Comments

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...